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Abstract
Background: DJ-1 has been thought as a candidate biomarker for Parkinson’s disease (PD). It was found reduced in
PD brains, CSF and saliva, although there were conflicting results. How DJ-1 expression may be regulated is not
clear. Recently, blood-based DNA methylation represents a highly promising biomarker for PD by regulating the
causative gene expression. Thus, in this study, we try to explore whether blood-based DNA methylation of DJ-1
could be used as a biomarker to differentiate PD patients from normal control (NC), and whether DNA methylation
could regulate DJ-1 expression in a SH-SY5Y cell model.
Methods: Forty PD patients and 40 NC were recruited in this study. DNA was extracted from peripheral blood
leukocytes (PBLs). Methylation status of two CpG islands (CpG1 and CpG2) in promoter region of DJ-1 was explored
by bisulfite specific PCR-based sequencing method. Methylation inhibitor 5-Aza-dC was used to treat SH-SY5Y cell
line, DJ-1 level was detected in both mRNA and protein level.
Results: CpG sites in these two CpG islands (CpG1 and CpG2) of DJ-1 were unmethylated in both PD and NC
group. In SH-SY5Y cell model treated by methylation inhibitor, there was no significant change of DJ-1 expression
in either mRNA level or protein level.
Conclusions: Our results indicated that DNA methylation inhibitor didn’t alter DJ-1 gene expression in SH-SY5Y cell
model, and DNA methylation of DJ-1 promoter region in PBLs level might not be an efficient biomarker for PD
patients.
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Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disorders, pathologically character-
ized by a progressive degeneration of dopaminergic neu-
rons and the presence of intracytoplasmic Lewy bodies
(LBs). The mechanisms responsible for neuronal degen-
eration in PD are complex and remain to be fully
elucidated.
Mutations of DJ-1 are linked to autosomal recessive
early-onset PD [1]. Extensive studies showed that DJ-1
has neuroprotective functions in anti-oxidative stress,
anti-inflammation, mitochondrial regulation [2]. Loss of
DJ-1 function was shown to cause autosomal recessive
PD [1]. In sporadic PD patients, the level of total DJ-1
protein was significantly reduced in the substantia nigra
(SN) and CSF [3–5], although there were conflicting re-
sults [6]. These results suggested that lower DJ-1 level in
PD patients may contribute to the pathogenesis of PD.
However, the molecular mechanisms underlying the
decreased DJ-1 level are not yet clear.
In recent years, epigenetic mechanisms such as DNA
methylation, histone modification, chromatin remodel-
ing and non-coding RNA regulation have been
evidenced to play a role in regulating gene expression in
neurodegenerative diseases [7–9]. DNA methylation at
the 5-carbon position of cytosine residues located in di-
nucleotide CpG sites has the specific effect of reducing
gene expression and unmethylated CpG sites are mostly
linked to gene activation [10]. Reduced CpG island
methylation in intron 1 of SNCA has been evidenced in
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PD brain tissue [11, 12], and hypomethylation of CpG
was associated with increased a-synuclein expression
[12]. Our previous results showed that the hypomethyla-
tion of SNCA in PD can also be detected in the blood-
based DNA methylation [13]. Eliezer Masliah et al.
identified concordant methylation alterations in brain
and blood by investigating genome-wide DNA methyla-
tion in brain and blood samples from PD patients and
NC [14]. These reports from both of Eliezer Masliah et
al. and us indicated that DNA extracted from leukocytes
in peripheral blood might be a potential effective nonin-
vasive source for screening epigenetic biomarker for PD
diagnosis. Until now, no data on the methylation status
of DJ-1 has been reported. In our study, we aimed to de-
tect whether there was differential DNA methylation of
DJ-1 in the peripheral blood between PD and NC groups
and determine whether DNA methylation of DJ-1 in
peripheral blood could represent the reduced expression
of DJ-1 in PD patients. In SH-SY5Y cell model we tested
whether DNA methylation can regulate DJ-1 expression
by using methylation inhibitor.
Methods
Subjects
Forty PD patients, diagnosed by the UK PD brain bank
criteria, were enrolled from the Department of
Neurology, Ruijin Hospital affiliated to Shanghai Jiao
Tong University School of Medicine, Shanghai, China;
40 NC were recruited from our previous epidemio-
logical studies. For each subject, 5 ml of blood samples
and clinical data, such as name, gender, age, age of on-
set, duration, disease stage (H-Y stage) were collected.
The PD and NC groups were well matched for age (PD:
63.7 ± 6.16 years; NC: 61.28 ± 9.21 years, p = 0.228) and
gender (PD: 24/16; NC: 24/16). All the subjects have
signed the informed consent form, and the study was
approved by the Ruijin Hospital Ethics Committee,
Shanghai Jiao Tong University School of Medicine.
DNA extraction and bisulfite specific PCR-based
sequencing method
Genomic DNA was extracted from peripheral blood
according to the standard procedures. CPGPLOT
(http://emboss.bioinformatics.nl/cgi-bin/emboss/cpgplot)
was used to identify and plot CpG islands in DJ-1
promoter region. Primer3 (http://frodo.wi.mit.edu/) was
used to design PCR bisulfite conversion-specific primers
(Table 1).
Bisulfite Specific PCR-based sequencing method was
described in our previous report [13]. 1 μg DNA was
treated with EZ DNA Methylation-GoldKit (ZYMO RE-
SEARCH) following the manufacture’s protocol. After
bisulfite conversion, unmethylated cytosines were con-
verted to uracils, the converted product was purified
followed by PCR amplification and sequencing. A 20 μl
mixture was prepared for each reaction and included 1×
HotStarTaq buffer, 2.0 mM Mg2+, 0.2 mM dNTP,
0.2 μM of each primer, 1 U HotStarTaq polymerase
(Qiagen Inc.) and 1 μl template DNA. The cycling pro-
gram was 95 °C for 15 mins; 11 cycles of 94 °C for 20s,
60–0.5 °C per cycle for 40 s, 72 °C for 1 min; 24 cycles
of 94 °C for 20 s, 54 °C for 30 s, 72 °C for 1 min; 72 °C
for 2 mins. 1U SAP and 6U Exo I were added into 8 μl
PCR products for PCR purification. The mixtures were
incubated at 37 °C for 60mins, followed by incubation at
70 °C for 10mins. In PCR amplification, the uracils were
amplified as thymines, whereas 5-MeC residues were
amplified as cytosines. The PCR products were puri-
fied to remove any primer dimers and sequenced on
an ABI 3730 XL analyzer (Applied Biosystems and
Life Technologies, USA). DNA methylation in the
PCR target region was then read by scoring the
remaining cytosine residues in the sequence. The de-
gree of methylation at each CpG site from the direct
sequencing profile was estimated by measuring the
relative peak height of the cytosine (C) versus cyto-
sine plus thymine (T) profile (C/(C + T)%). As this
can only be regarded as semi-quantitative, the degree
Table 1 Primers for PCR assays
Primer Sequence (5’ > 3’) Tm (°C) Amplicon (bp)
DJ-1- CpG1-methylation-PCR-F GTTYGGGAGGTTTGGATTAGAGTT 56 170
DJ-1- CpG1-methylation-PCR-R ACRACTCRATCCCACATAATACCC




DJ-1- Realtime-F CGGGGTGCAGGCTTGTAAA 58 150
DJ-1- Realtime-R TCCGGTTTTCCTGCTCCTTC
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of methylation was expressed as 0, 25, 50, 75 or
100 %.
Cell culture and treatment with 5-Aza-dC
SH-SY5Y cells (ATCC) were cultured in DMEM with
10 % FBS, 100 U/ml penicillin/streptomycin (Invitrogen)
and maintained at 37 °C with 5 % CO2. SH-SY5Y cells
were chemically treated with 5-Aza-dC (2.5 or 5 mM;
Sigma). Real time PCR and Western blot were used to
detect the mRNA and protein level of DJ-1. Total RNA
was extracted from SH-SY5Y cells after 24 h 5-Aza-dC
treatment by a standard method with TRIZOL Reagent
(Invitrogen), and reverse-transcribed by using the Prime-
Script® RT reagent Kit (Takara) according to the manufac-
ture’s instruction. The mRNA levels were detected
through real-time PCR by a standard method with Real-
time PCR Master Mix (SYBR Green) kit (Takara). The
primers for real-time PCR have been summarized in
Table 1. We extracted the total protein of SH-SY5Y cells
after 5-Aza-dC 48 h treatment. Rabbit anti-DJ-1 antibody
(1:1000, sigma) were used for immunoblotting. The
results were analyzed in three independent experiments.
Statistical analysis
Statistical analysis was performed using SPSS13.0 and
P < 0.05 was considered as significant. Statistical ana-
lysis included t tests for age. One-way ANOVA was
used to evaluate the differences in mRNA and protein
levels among SH-SY5Y cells treated by AZA, DMSO
and mock groups.
Table 2 Clinical characteristics of subjects
NC (n = 40) PD (n = 40) P-Value
Age, years
mean ± sd(lowest,highest)













– 5 ± 2.7(2,14) –
Fig 1 The two CpG islands in DJ-1. a Location of two CpG islands in DJ-1 (NM_001123377). b Sequence of CpG-1 islands in the promoter region
of DJ-1(a), sequence of CpG-2 islands in exon 1 of DJ-1(b)
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Results
1. Demographic characteristics
The clinical characteristics are listed in Table 2.
Each group comprised 24 men and 16 women,
and there was no significant difference in age
(P = 0.228) between the PD patients (63.7 ±
6.16 years) and NC (61.28 ± 9.21 years). Among
the PD patients, 28 had mild degree of the disease
(H &Y stage 1–2), 8 moderate (H& Y stage 3), and
4 severe (H&Y stage 4–5). Disease duration of 40
PD patients was 5 ± 2.7 years.
2. DNA Methylation of DJ-1 promoter region detected
by Bisulfite specific PCR-based sequencing method
Based on the NCBI database, the promoter region
of human DJ-1 gene (NM_001123377) has two
CpG islands (CGIs), locating at−1545 ~
−1244 bp(CpG1),−1178 ~−732 bp(CpG2)
upstream of the translation initiation site
(Fig. 1a). CpG1 has 15 CpG sequences (Fig. 1b, a).
CpG2 contains 21 CpG sequences (Fig. 1b, b). Bi-
sulfite specific PCR-based sequencing method was
used to examine the average methylation level at
each CpG site (See methods). Our results showed
that all the CpG sites probed in the two CGIs
were unmethylated in both PD and NC (Fig. 2).
The stable unmethylated status of CpG sites in
both PD and NC group indicated that CpG
methylation in the promoter region of DJ-1 in
PBLs might have very limited or no regulatory ef-
fects on DJ-1 expression.
3. No effects of methylation inhibitor on the DJ-1
expression in SH-SY5Y cell model
Previous whole genome bisulfite sequencing
(WGBS) study showed that DNA methylation can
be detected in various regions, including CGIs, gene
Fig 2 Bisulfite specific PCR-based sequencing analysis of two CpG islands methylation in 40 PD patients and 40 normal controls. a and b Unmethylated
cytosines (c) were converted to uracil (U) after bisulfite treatment and amplified as thymines (T) in PCR amplication. Unmethylated CpG sites 1–5 in
CpG1 island and CpG sites 9–16 in CpG2 island were shown here as an example. c and d All the CpG sites of these two CpG islands
were unmethylated. Here are the methylation of CpG1 island and CpG2 island from 5 PD and 5 NC cases, and the rest cases showed the
exact same methylation pattern
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bodies and tandem repeating-containing regions
[15]. Moreover, methylation levels in these regions
can regulate the transcription levels [15, 16].
Although the CpG sites probed in this study were
unmethylated in both PD and NC group, the other
CpG sites out of the promoter region haven’t been
determined. In order to test whether CpG methyla-
tion level can regulate the DJ-1 expression, methyla-
tion inhibitor 5-Aza-dC was used to demethylate
the CpG sites in a SH-SY5Y cell model, then DJ-1
expression was detected in the mRNA and protein
level. Our results showed DJ-1 expression didn’t
have significant change in both the mRNA and
protein level in SH-SY5Y cells treated with 2.5 mM
or 5 mM 5-Aza-dC compared with the untreated
cells (Fig. 3). Thus, the results indicated that DNA
methylation had no regulatory effects on DJ-1
expression in SH-SY5Y cell model.
Discussion
PD can begin years before the appearance of clinical
motor symptoms when a significant number of nigros-
triatal dopaminergic neurons have already been degener-
ated. The detection of PD prior to the emergence of
motor symptoms is important for early diagnosis, neuro-
protective treatment, monitoring disease progression
and response to therapy. Thus, reliable biomarkers,
which can represent a pathological process and can be
easily detected, are needed. DJ-1 detected from brain [3],
CSF [4, 5] and saliva [17] has been thought as a
candidate biomarker of PD [18]. Recently, blood-based
DNA methylation represents a highly promising bio-
marker for PD [13, 14] by regulating the causative gene
expression. Thus, in the present study, we explored
whether there was different DNA methylation level of
DJ-1 in the PBLs between PD patients and NC.
Our results showed that in the two CGIs that we
probed, all the CpG sites were unmethylated in both PD
group and NC group, indicating that CpG methylation in
the promoter region of DJ-1 in PBLs might have very lim-
ited or no regulatory effects on DJ-1 expression and could
not be used as a biomarker to reflect DJ-1 expression
changes in brains of PD patients and NC. However, previ-
ous WGBS study showed that DNA methylation can be
detected in various regions, including CGIs, gene bodies
and tandem repeating-containing regions [15]. Methyla-
tion levels in these regions can also regulate the transcrip-
tion levels [15, 16]. Bisulfite specific PCR-based
sequencing method used in our study only favored those
CpG sites contained within CGIs and promoter regions
[16]. Thus all other CpG sites out of the CGIs and pro-
moter region can’t be probed by this method. In order to
confirm whether CpG methylation can regulate the DJ-1
expression, we used methylation inhibitor to treat SH-
SY5Y cells, then DJ-1 expression was detected in the
mRNA and protein level. Our results revealed that there
was no significant expression change of DJ-1 between the
cells treated with methylation inhibitor and non-treated
cells. Thus, our results indicated that DNA methylation
might not be the key factor in regulating DJ-1 expression.
Fig 3 The mRNA and protein levels of DJ-1 did not change in 5-Aza-dC treated SH-SY5Y cells. Western blot and RT-PCR showed no significant
change of DJ-1 protein level (a & b) and mRNA level (c) among 5-Aza-dC treated, DMSO treated and mock cells. Bar plot indicated the statistical
analysis of DJ-1 protein level (b) and mRNA level (c) (Mean ± SD, *p < 0.05)
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Generally, gene expression can be regulated in three differ-
ent levels, transcriptional, mature mRNA processing and
translational level. In the transcriptional level, both Sp1 and
X-box-binding protein-1S (XBP-1S) were identified as tran-
scription regulatory factor interacting with the DJ-1 promoter,
thereby enhancing its promoter trans-activation, mRNA
levels and protein expression [19, 20]. In mRNA processing
level,miR-494was found to decreaseDJ-1 expression by bind-
ing to the 3’UTR of DJ-1 [21]. Till now, the epigenetic mech-
anism in modulating DJ-1 expression has not been fully
explored. Zhou W et al. reported that phenylbutyrate, a
HDAC inhibitor, can up-regulate the DJ-1 protein, indicating
that DJ-1 expression can be regulated by histone modification
[22]. In our study, we explored the possibility that whether DJ-
1 expression can be regulated by the DNA methylation. We
did not find differential CpG sites methylation in the CGIs of
DJ-1 promoter region between PD and NC group, and there
was no significant change of DJ-1 expression in a SH-SY5Y
cell model treated bymethylation inhibitor.
However, there were some limitations in our study. First,
the sample size is small, and brain tissue as a standard con-
trol is not available in our country. Second, bisulfite specific
PCR-based sequencing method used in our study is a con-
venient and economic method for DNA methylation screen-
ing, but it is a semi-quantitative method and only favored
those CpG sites in the CGIs and promoter region [16]. Usu-
ally, we use PCR-based sequencing method for screening, if
it provides any clue of different methylation, we would use
bisulfite specific cloning-based sequencing, which is a more
accurate and sensitive method to test the cytosine methyla-
tion at each CpG site in individual molecules [23], for fur-
ther study. In this study, no methylated CpG sites were
found in both PD and NC. Thus, the results would be the
same even bisulfite specific cloning-based sequencing was
used. As bisulfite specific PCR-based method only favors
those CpG sites in CGIs and promoter region, in order to
detect any regulatory effect of CpG sites methylation out of
CGIs and promotor region on DJ-1 expression, we treated
SH-SY5Y cells with methylation inhibitor and tested the DJ-
1 expression level from both the mRNA and protein level,
and our results confirmed no regulatory effects of DNA
methylation on DJ-1 expression. In this study, we tried our
best to get the truth, but the objective limits still exist. For
further study, WGBS would be a good way to obtain an un-
biased and more complete representation of the methylome
by testing in both human brain tissue and PBLs.
Conclusions
CpG sites are unmethylated in DJ-1 promoter region of
PBLs from both PD patients and NC. DNA methylation in-
hibitor didn’t alter DJ-1 gene expression in SH-SY5Y cell
model. Our results indicated that methylation status of DJ-
1 had no obvious regulatory effects on DJ-1 expression, and
might not be an efficient biomarker for PD patients.
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